Background: This phase III post-NC trial evaluates if CWRNRT post-Mx or whole breast irradiation (WBI) with RNRT after BCS significantly reduces the IBCR-FI rate in pts with PAx nodes that are negative after NC. Secondary aims are OS, LRR-FI, DRFI, DFS-DCIS, second primary cancer, and comparison of RT effect on cosmesis in reconstructed Mx pts. Correlative science examines RT effect by tumor subtype, molecular outcome predictors for residual disease pts, and predictors for the degree of reduction in loco-regional recurrence. Methods: Clinical T1-3, N1 IBC PAx nodes (FNA or core needle biopsy) pts complete ≥ 12 wks of NC (anthracycline and/or taxane). HER2+ pts receive anti-HER2 therapy (tx). Following NC BCS or Mx, sentinel node biopsy ( ≥ 3 nodes) and/or Ax dissection with histologically negative nodes is performed. ER/PR and HER-2neu status before NC required. Pts receive required systemic tx. Radiation credentialing with a facility questionnaire/case benchmark required. Randomization for Mx pts is to no CWRNRT or CWRNRT and for BCS pts to WBI or WBI RNRT. Statistics: 1636 pts to be enrolled over 5 yrs (definitive analysis at 7.5 yrs). Study is powered at 80% to test that RT reduces the annual hazard rate of events for IBCR-FI by 35% for an absolute risk reduction of 4.6% (5 yr cumulative rate). Intent-to-treat analysis with 3 interim analyses (43, 86, and 129 events) and a 4th/final analysis at 172 events. Pt-reported outcomes focusing on RT effect will be provided by 736 pts before randomization and at 3, 6, 12, and 24 mos. Accrual as of 1/29/16 is 266. (Drs. G Unzeitig, Doctor's Hospital of Laredo, J Stromberg, Beaumont Hospital, T Muanza, Jewish General Hospital, and W Warlick, Novant Health Presbyterian Medical Center, are acknowledged for high accrual.) Contacts: Questions: NRG Oncology Pgh Clin Coord Dpt: 1-800-477-7227 or ccd@nsabp.org. Support: U10 CA-2166; -180868, -180822; 189867; Elekta Clinical trial information: NCT01872975